Benchmark Capital Advisors - GALECTIN THERAPEUTICS INC ownership

GALECTIN THERAPEUTICS INC's ticker is GALT and the CUSIP is 363225202. A total of 64 filers reported holding GALECTIN THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is 1.50 and the average weighting 0.0%.

Quarter-by-quarter ownership
Benchmark Capital Advisors ownership history of GALECTIN THERAPEUTICS INC
ValueSharesWeighting
Q4 2018$764,000
-42.9%
222,7000.0%0.76%
-24.5%
Q3 2018$1,338,000
-5.1%
222,700
+0.5%
1.01%
-5.6%
Q2 2018$1,410,000
+34.2%
221,7000.0%1.07%
+28.3%
Q1 2018$1,051,000
+69.8%
221,700
+19.7%
0.83%
+72.0%
Q4 2017$619,000
+48.8%
185,200
-4.6%
0.48%
+49.5%
Q3 2017$416,000
-13.0%
194,2000.0%0.32%
-14.3%
Q2 2017$478,000
+6.9%
194,2000.0%0.38%
+6.8%
Q1 2017$447,000
+130.4%
194,200
-2.0%
0.35%
+119.3%
Q4 2016$194,000
+44.8%
198,200
+67.7%
0.16%
+59.4%
Q3 2016$134,000
+52.3%
118,200
+98.3%
0.10%
+40.3%
Q2 2016$88,000
+3.5%
59,6000.0%0.07%
-4.0%
Q1 2016$85,000
-13.3%
59,6000.0%0.08%
-9.6%
Q4 2015$98,000
-39.9%
59,600
-14.4%
0.08%
-37.6%
Q3 2015$163,000
-16.4%
69,600
-2.8%
0.13%
-2.9%
Q2 2015$195,000
-41.6%
71,600
-28.1%
0.14%
-37.7%
Q1 2015$334,000
-3.7%
99,600
-0.5%
0.22%
-5.6%
Q4 2014$347,000
-74.2%
100,100
-62.6%
0.23%
-50.2%
Q3 2014$1,344,000
+9.4%
267,300
+200.3%
0.47%
-39.1%
Q2 2014$1,229,000
-5.5%
89,000
+4.7%
0.77%
-14.9%
Q1 2014$1,301,000
+89.4%
85,0000.0%0.90%
+89.9%
Q4 2013$687,000
+5.2%
85,000
+29.8%
0.48%
+1.5%
Q3 2013$653,000
+668.2%
65,500
+227.5%
0.47%
+610.6%
Q2 2013$85,00020,0000.07%
Other shareholders
GALECTIN THERAPEUTICS INC shareholders Q3 2018
NameSharesValueWeighting ↓
Cutter & CO Brokerage, Inc. 129,488$248,6170.07%
Geneos Wealth Management Inc. 417,350$801,3120.04%
SHEPHERD KAPLAN KROCHUK, LLC 12,000$23,0400.02%
RETIREMENT GUYS FORMULA LLC 11,500$22,0800.02%
Vivaldi Capital Management LP 19,261$36,9810.01%
OSAIC HOLDINGS, INC. 3,275,192$6,288,3450.01%
Traynor Capital Management, Inc. 34,707$66,6380.01%
Atria Wealth Solutions, Inc. 259,800$498,8160.01%
BARRETT & COMPANY, INC. 4,984$9,5690.01%
Wealthspire Advisors, LLC 183,862$353,0160.01%
View complete list of GALECTIN THERAPEUTICS INC shareholders